Clinical Trials
35 trialsNCT05041309 2026-05-14
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Gilead Sciences
Enrolling by invitation
NCT07474051 2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
NCT05332054 2026-03-12
LTFS
Caribou Biosciences, Inc.
Enrolling by invitation
NCT07154823 2026-03-03
Aquarius
Tempus AI
Recruiting
NCT04307134 2025-12-31
Besponsa Post Marketing Surveillance Study
Pfizer
Completed
NCT06208878 2025-08-14
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
CRISPR Therapeutics
Enrolling by invitation
NCT05549232 2025-07-23
Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital
Hemanext
Completed
NCT05768269 2025-06-25
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
Century Therapeutics, Inc.
Recruiting
NCT06925685 2025-04-13
Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
Allogene Therapeutics
Enrolling by invitation
NCT05282108 2025-03-26
CARCML
Hikma Pharmaceuticals LLC
Recruiting
NCT05735704 2025-03-26
SANGUINE
JaxBio Ltd
Unknown
NCT04889937 2025-03-11
PC004
Leuko Labs, Inc.
Completed
NCT02636855 2025-03-04
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Adaptimmune
Completed
NCT04466059 2024-12-17
BELUGA
Munich Leukemia Laboratory
Recruiting
NCT05046444 2024-12-17
SIRIUS
Munich Leukemia Laboratory
Recruiting
NCT05819762 2024-12-04
Evaluation of ClearLLab LS Screening Panel
Beckman Coulter, Inc.
Completed
NCT05467449 2024-02-13
DxFLEX 10C Clinical Study
Beckman Coulter, Inc.
Completed
NCT04389541 2023-08-14
INFINITY
iOMEDICO AG
Completed
NCT05889806 2023-06-05
AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens)
Audubon Bioscience
Enrolling by invitation
NCT01792882 2023-02-28
GBCPRT0008
Global BioClinical
Withdrawn
NCT04093622 2022-08-29
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
Fate Therapeutics
Terminated
NCT04264767 2022-06-08
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
Nucleix Ltd.
Completed
NCT03727009 2021-02-03
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Exact Sciences Corporation
Terminated
NCT03391791 2021-01-07
Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors
Adaptimmune
Terminated
NCT02164071 2019-11-18
GAH
Celgene
Completed
NCT02842229 2017-07-26
A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms
Celgene
Completed
NCT01254318 2016-11-02
TRAFIC
Merck Sharp & Dohme LLC
Completed
NCT02188290 2015-10-06
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
Kiadis Pharma
Completed
NCT00440479 2015-04-16
ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
Janssen-Cilag B.V.
Completed
NCT01060462 2014-05-15
Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients
Janssen Korea, Ltd., Korea
Completed
NCT00440765 2014-01-14
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
Janssen-Cilag B.V.
Completed
NCT01021683 2013-08-12
The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants
Janssen Korea, Ltd., Korea
Completed
NCT01706562 2013-02-20
A Study of Empirical Antifungal Therapy With Itraconazole
Janssen Korea, Ltd., Korea
Completed
NCT00596999 2012-04-10
HPDSC
Celgene
Unknown
NCT00195533 2009-11-16
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
Wyeth is now a wholly owned subsidiary of Pfizer
Completed